ONTILYV

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug ONTILYV contains one active pharmaceutical ingredient (API):

1	Opicapone UNII Y5929UIJ5N - OPICAPONE
	Opicapone is a peripheral, selective and reversible catechol-O-methyltransferase (COMT) inhibitor endowed with a high binding affinity (sub-picomolar). Opicapone is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease, leading to an increase of levodopa plasma levels thereby improving the clinical response to levodopa.
	Read more about Opicapone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ONTILYV Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N04BX04		N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BX Other dopaminergic agents
Discover more medicines within N04BX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1877283, 1877294, 1877306, 1877317, 1877328, 1877339, 1877340, 1877351, 1877362, 1877373
IT	Agenzia del Farmaco	049963010, 049963022, 049963034, 049963046, 049963059, 049963061, 049963073, 049963085, 049963097, 049963109
LT	Valstybinė vaistų kontrolės tarnyba	1094285, 1094286, 1094287, 1094288, 1094289, 1094290, 1094291, 1094292, 1094293, 1094294
PL	Rejestru Produktów Leczniczych	100467786, 100467793